Scholarlink

Background <p>R0 resection is the standard for mass-forming cholangiocarcinoma (MFCCC). R1vasc resection (tumor–vessel detachment) yielded results comparable to R0 and superior to parenchymal-tumor exposure (R1par) for hepatocellular carcinoma and colorectal liver metastases. This study aims to clarify R1vasc outcomes for MFCCC.</p> Patients and Methods <p>Margin status of patients with MFCCC undergoing resection between 2008 and 2022 was assessed to determine the oncological efficacy of R1vasc regarding survival and hepatic recurrence.</p> Results <p>The study analyzed 125 patients: 68 (54.4%) R0, 18 (14.4%) R1vasc, 24 (19.2%) R1par, and 15 (12.0%) R1vasc + par. Tumor size was similar between R0 (4.4&#xa0;cm, range 1.5–19.0) and R1vasc (4.3&#xa0;cm, range 2.3–14.5, <i>p </i>= 0.754) but larger for R1par (8.2&#xa0;cm, range 2.5–15.0, <i>p </i>= 0.005) and R1vasc + par (9.0&#xa0;cm, range 5.0–17.0, <i>p </i>&lt; 0.001). The median overall survival (OS) was comparable for R0 [64.8 months; 95% confidence interval (CI): 50.0–79.6], R1vasc (54.4 months; 95% CI 19.6–89.2; <i>p </i>= 0.932), and R1vasc + par (62.0 months; 95% CI 35.6–88.5; <i>p </i>= 0.989). R1par showed lower OS (26.8 months; 95% CI 16.1–37.6; <i>p </i>= 0.134). Local recurrence was higher for R1par (45.8%, <i>p </i>&lt; 0.0001) compared with R0 (10.3%) and similar for R1vasc (16.6%) and R1vasc + par (20.0%). Survival after hepatic recurrence was higher for R1vasc compared with R1par (<i>p </i>= 0.041).</p> Conclusions <p>R1vasc is a valid option for increasing resectability in patients with MFCCC, with OS being comparable to R0. R1vasc + par may be necessary for larger tumors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-Term Outcomes According to Surgical Margin in Mass-Forming Cholangiocarcinoma: The Role of R1vasc

  • 期刊论文

  • 发表日期：

    2025年2月28日

查看全文
  • Flavio Milana,
  • Fabio Procopio,
  • Eleonora Calafiore,
  • Simone Famularo,
  • Guido Costa,
  • Jacopo Galvanin,
  • Bruno Branciforte,
  • Guido Torzilli

摘要

Background

R0 resection is the standard for mass-forming cholangiocarcinoma (MFCCC). R1vasc resection (tumor–vessel detachment) yielded results comparable to R0 and superior to parenchymal-tumor exposure (R1par) for hepatocellular carcinoma and colorectal liver metastases. This study aims to clarify R1vasc outcomes for MFCCC.

Patients and Methods

Margin status of patients with MFCCC undergoing resection between 2008 and 2022 was assessed to determine the oncological efficacy of R1vasc regarding survival and hepatic recurrence.

Results

The study analyzed 125 patients: 68 (54.4%) R0, 18 (14.4%) R1vasc, 24 (19.2%) R1par, and 15 (12.0%) R1vasc + par. Tumor size was similar between R0 (4.4 cm, range 1.5–19.0) and R1vasc (4.3 cm, range 2.3–14.5, p = 0.754) but larger for R1par (8.2 cm, range 2.5–15.0, p = 0.005) and R1vasc + par (9.0 cm, range 5.0–17.0, p < 0.001). The median overall survival (OS) was comparable for R0 [64.8 months; 95% confidence interval (CI): 50.0–79.6], R1vasc (54.4 months; 95% CI 19.6–89.2; p = 0.932), and R1vasc + par (62.0 months; 95% CI 35.6–88.5; p = 0.989). R1par showed lower OS (26.8 months; 95% CI 16.1–37.6; p = 0.134). Local recurrence was higher for R1par (45.8%, p < 0.0001) compared with R0 (10.3%) and similar for R1vasc (16.6%) and R1vasc + par (20.0%). Survival after hepatic recurrence was higher for R1vasc compared with R1par (p = 0.041).

Conclusions

R1vasc is a valid option for increasing resectability in patients with MFCCC, with OS being comparable to R0. R1vasc + par may be necessary for larger tumors.